Comparative Pharmacology
Head-to-head clinical analysis: CINOXACIN versus MOXIFLOXACIN HYDROCHLORIDE.
Head-to-head clinical analysis: CINOXACIN versus MOXIFLOXACIN HYDROCHLORIDE.
CINOXACIN vs MOXIFLOXACIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
1 g orally twice daily for 7-14 days.
400 mg orally or intravenously once daily for most indications; duration varies by indication.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digitoxin
"Cinoxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCinoxacin + Deslanoside
"Cinoxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCinoxacin + Acetyldigitoxin
"Cinoxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 12-14 hours in healthy adults, allowing once-daily dosing. This is extended in severe renal impairment (creatinine clearance <30 mL/min) and in the elderly.
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Approximately 20% of a dose is excreted unchanged in urine, with about 25% recovered as a glucuronide conjugate (M1) and a sulfate conjugate (M2). Biliary/fecal excretion accounts for about 55% of the dose, with a portion undergoing enterohepatic recirculation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic